Nanomaterial-assisted CRISPR gene-engineering – A hallmark for triple-negative breast cancer therapeutics advancement

Farheen, Jabeen; Hosmane, Narayan S.; Zhao, Ruibo; Zhao, Qiu; Iqbal, M. Zubair; Kong, Xiangdong

doi:10.1016/j.mtbio.2022.100450

Cited by 8 publications

(8 citation statements)

References 333 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to this concern, CRISPR based therapy is rising attention towards cancer treatment [ 164 ]. Clustered regularly interspaced short palindromic repeats abbreviated as CRISPR is the latest genetic editing tool which upon combination with nanotechnology stands to be a promising therapeutic approach for treating cancers [ 165 ]. Zhang et al fabricated PEG phospholipid-modified cationic lipid nanoparticles (PLNP) for CRISPR/Cas9 to enhance its transfection into the cellular site.…”

Section: Emerging Nanotechnology Based Delivery Approaches Toward Tnb...mentioning

confidence: 99%

Recent Advances in Targeted Nanocarriers for the Management of Triple Negative Breast Cancer

et al. 2023

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is a life-threatening form of breast cancer which has been found to account for 15% of all the subtypes of breast cancer. Currently available treatments are significantly less effective in TNBC management because of several factors such as poor bioavailability, low specificity, multidrug resistance, poor cellular uptake, and unwanted side effects being the major ones. As a rapidly growing field, nano-therapeutics offers promising alternatives for breast cancer treatment. This platform provides a suitable pathway for crossing biological barriers and allowing sustained systemic circulation time and an improved pharmacokinetic profile of the drug. Apart from this, it also provides an optimized target-specific drug delivery system and improves drug accumulation in tumor cells. This review provides insights into the molecular mechanisms associated with the pathogenesis of TNBC, along with summarizing the conventional therapy and recent advances of different nano-carriers for the management of TNBC.

show abstract

Section: Emerging Nanotechnology Based Delivery Approaches Toward Tnb...mentioning

confidence: 99%

Recent Advances in Targeted Nanocarriers for the Management of Triple Negative Breast Cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Gene editing based on Clustered regularly interspaced short palindromic repeat (CRISPR)-nuclease Cas9 ribonucleoprotein system has emerged as a front-runner in cancer therapeutic strategies, including immunotherapy. The system uses a single stranded RNA guide sequence to recognize and cleave the target DNA strands using Cas9 [ 99 ]. The cleaved strands when allowed to undergo repair may result in modifications such as insertion or deletion [ 100 ].…”

Section: Recent Developments In Cancer Immunotherapymentioning

confidence: 99%

Emerging Trends in Nano-Driven Immunotherapy for Treatment of Cancer

2023

View full text Add to dashboard Cite

Despite advancements in the development of anticancer medications and therapies, cancer still has the greatest fatality rate due to a dismal prognosis. Traditional cancer therapies include chemotherapy, radiotherapy, and targeted therapy. The conventional treatments have a number of shortcomings, such as a lack of selectivity, non-specific cytotoxicity, suboptimal drug delivery to tumour locations, and multi-drug resistance, which results in a less potent/ineffective therapeutic outcome. Cancer immunotherapy is an emerging and promising strategy to elicit a pronounced immune response against cancer. Immunotherapy stimulates the immune system with cancer-specific antigens or immune checkpoint inhibitors to overcome the immune suppressive tumour microenvironment and kill the cancer cells. However, delivery of the antigen or immune checkpoint inhibitors and activation of the immune response need to circumvent the issues pertaining to short lifetimes and effect times, as well as adverse effects associated with off-targeting, suboptimal, or hyperactivation of the immune system. Additional challenges posed by the tumour suppressive microenvironment are less tumour immunogenicity and the inhibition of effector T cells. The evolution of nanotechnology in recent years has paved the way for improving treatment efficacy by facilitating site-specific and sustained delivery of the therapeutic moiety to elicit a robust immune response. The amenability of nanoparticles towards surface functionalization and tuneable physicochemical properties, size, shape, and surfaces charge have been successfully harnessed for immunotherapy, as well as combination therapy, against cancer. In this review, we have summarized the recent advancements made in choosing different nanomaterial combinations and their modifications made to enable their interaction with different molecular and cellular targets for efficient immunotherapy. This review also highlights recent trends in immunotherapy strategies to be used independently, as well as in combination, for the destruction of cancer cells, as well as prevent metastasis and recurrence.

show abstract

“…With the rapid development of nanotechnology, nanomaterials which can be manipulated on atomic and molecular scale are applied in medicine (Chai et al, 2022;Wang et al, 2022c;Zhang et al, 2022d;Farheen et al, 2022;Yang et al, 2022). Novel nanomaterials have demonstrated outstanding potentials in clinical applications with diverse functions (Filik et al, 2021;Li et al, 2022b;Kim et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

Progress and prospects of nanozymes for enhanced antitumor therapy

Zhao

Yuan

et al. 2022

Front. Chem.

View full text Add to dashboard Cite

Nanozymes are nanomaterials with mimicked enzymatic activity, whose catalytic activity can be designed by changing their physical parameters and chemical composition. With the development of biomedical and material science, artificially created nanozymes have high biocompatibility and can catalyze specific biochemical reactions under biological conditions, thus playing a vital role in regulating physiological activities. Under pathological conditions, natural enzymes are limited in their catalytic capacity by the varying reaction conditions. In contrast, compared to natural enzymes, nanozymes have advantages such as high stability, simplicity of modification, targeting ability, and versatility. As a result, the novel role of nanozymes in medicine, especially in tumor therapy, is gaining increasing attention. In this review, function and application of various nanozymes in the treatment of cancer are summarized. Future exploration paths of nanozymes in cancer therapies based on new insights arising from recent research are outlined.

show abstract

Nanomaterial-assisted CRISPR gene-engineering – A hallmark for triple-negative breast cancer therapeutics advancement

Cited by 8 publications

References 333 publications

Recent Advances in Targeted Nanocarriers for the Management of Triple Negative Breast Cancer

Recent Advances in Targeted Nanocarriers for the Management of Triple Negative Breast Cancer

Emerging Trends in Nano-Driven Immunotherapy for Treatment of Cancer

Progress and prospects of nanozymes for enhanced antitumor therapy

Contact Info

Product

Resources

About